These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 36650762)

  • 21. The resurgence risk of COVID-19 in China in the presence of immunity waning and ADE: A mathematical modelling study.
    Zhou W; Tang B; Bai Y; Shao Y; Xiao Y; Tang S
    Vaccine; 2022 Nov; 40(49):7141-7150. PubMed ID: 36328883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Projecting the COVID-19 immune landscape in Japan in the presence of waning immunity and booster vaccination.
    Sasanami M; Fujimoto M; Kayano T; Hayashi K; Nishiura H
    J Theor Biol; 2023 Feb; 559():111384. PubMed ID: 36528092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
    Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
    Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of SARS-CoV-2 vaccines on Covid-19 incidence and mortality in the United States.
    Fang F; Clemens JD; Zhang ZF; Brewer TF
    PLoS One; 2024; 19(4):e0301830. PubMed ID: 38656933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutralizing Activity Against SARS-CoV-2 Delta and Omicron Variants Following a Third BNT162b2 Booster Dose According to Three Homologous or Heterologous COVID-19 Vaccination Schedules.
    Choi JY; Lee YJ; Ko JH; Kim SH; Kim HJ; Lee HW; Jeong H; Kim TY; Jang YG; Hong HJ; Kim MS; Lee SE; Kim YG; Chung EJ; Lim H; Jang S; Kim K; Kim SS; Ahn JY; Choi JY; Kim YC; Park YS; Peck KR; Kim B
    Front Cell Infect Microbiol; 2022; 12():948014. PubMed ID: 35899050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination.
    Yang W; Shaman J
    medRxiv; 2021 Nov; ():. PubMed ID: 34845460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.
    Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y
    JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence - 25 U.S. Jurisdictions, April 4-December 25, 2021.
    Johnson AG; Amin AB; Ali AR; Hoots B; Cadwell BL; Arora S; Avoundjian T; Awofeso AO; Barnes J; Bayoumi NS; Busen K; Chang C; Cima M; Crockett M; Cronquist A; Davidson S; Davis E; Delgadillo J; Dorabawila V; Drenzek C; Eisenstein L; Fast HE; Gent A; Hand J; Hoefer D; Holtzman C; Jara A; Jones A; Kamal-Ahmed I; Kangas S; Kanishka F; Kaur R; Khan S; King J; Kirkendall S; Klioueva A; Kocharian A; Kwon FY; Logan J; Lyons BC; Lyons S; May A; McCormick D; ; Mendoza E; Milroy L; O'Donnell A; Pike M; Pogosjans S; Saupe A; Sell J; Smith E; Sosin DM; Stanislawski E; Steele MK; Stephenson M; Stout A; Strand K; Tilakaratne BP; Turner K; Vest H; Warner S; Wiedeman C; Zaldivar A; Silk BJ; Scobie HM
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):132-138. PubMed ID: 35085223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of Adapted COVID-19 Vaccines and Ability to Establish Herd Immunity against Omicron BA.1 and BA4-5 Variants of SARS-CoV-2.
    Plans-Rubió P
    Vaccines (Basel); 2023 Dec; 11(12):. PubMed ID: 38140240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.
    Tartof SY; Slezak JM; Fischer H; Hong V; Ackerson BK; Ranasinghe ON; Frankland TB; Ogun OA; Zamparo JM; Gray S; Valluri SR; Pan K; Angulo FJ; Jodar L; McLaughlin JM
    Lancet; 2021 Oct; 398(10309):1407-1416. PubMed ID: 34619098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term levels of protection of different types of immunity against the Omicron variant: a rapid literature review.
    Rodriguez Velásquez S; Biru LE; Hakiza SM; Al-Gobari M; Triulzi I; Dalal J; Varela CBG; Botero Mesa S; Keiser O
    Swiss Med Wkly; 2024 May; 154():3732. PubMed ID: 38749028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study.
    Castelli JM; Rearte A; Olszevicki S; Voto C; Del Valle Juarez M; Pesce M; Iovane AN; Paz M; Chaparro ME; Buyayisqui MP; Markiewicz MB; Landoni M; Giovacchini CM; Vizzotti C
    BMJ; 2022 Nov; 379():e073070. PubMed ID: 36450402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
    Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modeling waning and boosting of COVID-19 in Canada with vaccination.
    Childs L; Dick DW; Feng Z; Heffernan JM; Li J; Röst G
    Epidemics; 2022 Jun; 39():100583. PubMed ID: 35665614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Ferdinands JM; Rao S; Dixon BE; Mitchell PK; DeSilva MB; Irving SA; Lewis N; Natarajan K; Stenehjem E; Grannis SJ; Han J; McEvoy C; Ong TC; Naleway AL; Reese SE; Embi PJ; Dascomb K; Klein NP; Griggs EP; Konatham D; Kharbanda AB; Yang DH; Fadel WF; Grisel N; Goddard K; Patel P; Liao IC; Birch R; Valvi NR; Reynolds S; Arndorfer J; Zerbo O; Dickerson M; Murthy K; Williams J; Bozio CH; Blanton L; Verani JR; Schrag SJ; Dalton AF; Wondimu MH; Link-Gelles R; Azziz-Baumgartner E; Barron MA; Gaglani M; Thompson MG; Fireman B
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):255-263. PubMed ID: 35176007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population immunity to pre-Omicron and Omicron SARS-CoV-2 variants in US states and counties through December 1, 2021.
    Klaassen F; Chitwood MH; Cohen T; Pitzer VE; Russi M; Swartwood NA; Salomon JA; Menzies NA
    medRxiv; 2022 Mar; ():. PubMed ID: 34981078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination.
    Assawakosri S; Kanokudom S; Chansaenroj J; Suntronwong N; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanatorn T; Klinfueng S; Sudhinaraset N; Mongkolsapaya J; Wanlapakorn N; Honsawek S; Poovorawan Y
    Int J Infect Dis; 2022 Sep; 122():793-801. PubMed ID: 35863731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Previous COVID-19 Vaccination on Humoral Immunity 3 Months after SARS-CoV-2 Omicron Infection and Booster Effect of a Fourth COVID-19 Vaccination 2 Months after SARS-CoV-2 Omicron Infection.
    Kim J; Seo H; Kim HW; Kim D; Kwon HJ; Kim YK
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36366556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal SARS-CoV-2 vaccine allocation using real-time attack-rate estimates in Rhode Island and Massachusetts.
    Tran TN; Wikle NB; Albert E; Inam H; Strong E; Brinda K; Leighow SM; Yang F; Hossain S; Pritchard JR; Chan P; Hanage WP; Hanks EM; Boni MF
    BMC Med; 2021 Jul; 19(1):162. PubMed ID: 34253200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.